Access to Disease-Modifying Alzheimer's Therapies: Addressing Possible Challenges Using Innovative Payment Models
| Authors | |
|---|---|
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Value in health |
| Citation | |
| web | https://www.sciencedirect.com/science/article/pii/S1098301522020393?via%3Dihub |
| Doi | http://dx.doi.org/10.1016/j.jval.2022.06.003 |
| Keywords | disease-modifying therapies; payment; prescription drugs |
| Description | Objectives: Aduhelm is the first approved disease-modifying therapies (DMT) for Alzheimer disease (AD). Nevertheless, under current payment models, AD DMTs-especially because they treat broader populations-will pose challenges to patient access since costs may accrue sooner than benefits do. New payment approaches may be needed to address this difference in timing. |